MX2023000714A - Metodo de tratamiento de condiciones que responden a terapia con oxido nitrico. - Google Patents
Metodo de tratamiento de condiciones que responden a terapia con oxido nitrico.Info
- Publication number
- MX2023000714A MX2023000714A MX2023000714A MX2023000714A MX2023000714A MX 2023000714 A MX2023000714 A MX 2023000714A MX 2023000714 A MX2023000714 A MX 2023000714A MX 2023000714 A MX2023000714 A MX 2023000714A MX 2023000714 A MX2023000714 A MX 2023000714A
- Authority
- MX
- Mexico
- Prior art keywords
- nitric oxide
- methods
- treating conditions
- conditions responsive
- oxide therapy
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 239000002535 acidifier Substances 0.000 abstract 1
- 239000012159 carrier gas Substances 0.000 abstract 1
- 239000002840 nitric oxide donor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Medicinal Preparation (AREA)
Abstract
Se muestran y describen composiciones y métodos de tratamiento de condiciones en un sujeto que responden a tratamiento con óxido nítrico (NO). Estas composiciones pueden incluir una combinación de un compuesto de liberación de óxido nítrico, un agente acidificante y un portador en cantidades que liberan desde aproximadamente 1 ppm*min/ml hasta aproximadamente 500 ppm*min/ml de NO con base en 1 ml de la composición cuando se mide por liberación de No a partir de la composición por un período de 30 minutos en un flujo de un gas portador sustancialmente inerte a una velocidad de flujo de 1 litro por minuto y una presión de 1 atmósfera, acoplado a un detector de quimioluminiscencia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052805P | 2020-07-16 | 2020-07-16 | |
| PCT/IB2021/000505 WO2022013614A1 (en) | 2020-07-16 | 2021-07-16 | Methods of treating conditions responsive to nitric oxide therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000714A true MX2023000714A (es) | 2023-02-14 |
Family
ID=79556044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000714A MX2023000714A (es) | 2020-07-16 | 2021-07-16 | Metodo de tratamiento de condiciones que responden a terapia con oxido nitrico. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230285447A1 (es) |
| EP (1) | EP4125941A4 (es) |
| JP (1) | JP2023533588A (es) |
| CN (1) | CN116615188A (es) |
| AU (1) | AU2021307675A1 (es) |
| BR (1) | BR112023000788A2 (es) |
| CA (1) | CA3186075A1 (es) |
| MX (1) | MX2023000714A (es) |
| WO (1) | WO2022013614A1 (es) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6709681B2 (en) * | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| GB0119011D0 (en) * | 2001-08-03 | 2001-09-26 | Univ Aberdeen | Treatment of nail infections |
| WO2011155887A1 (en) * | 2010-06-07 | 2011-12-15 | Topical Pharma Ab | Kit for the treatment of onychomycosis by nitric oxide |
| CN103690490B (zh) * | 2012-08-23 | 2017-11-17 | 尼奥克斯(文莱)控股有限公司 | 基于微囊化化学试剂延时产生一氧化氮的系统和方法 |
| CA2930189A1 (en) * | 2013-10-18 | 2015-04-23 | Bovicor Pharmatech Inc. | Preparation and delivery of sustained nitric oxide releasing solutions |
| US20160051579A1 (en) * | 2014-03-14 | 2016-02-25 | Bovicor Pharmatech, Inc. | Nitric oxide treatment of bovine respiratory disease complex and other respiratory conditions |
| AU2015229626B2 (en) * | 2014-03-14 | 2021-05-20 | Sanotize Research And Development Corp. | Treating diseases using nitric oxide releasing solutions |
| US20170151277A1 (en) * | 2015-09-04 | 2017-06-01 | Bovicor Pharmatech Inc. | Enhanced immune response in cattle upon treatment with nitric oxide |
| US20190076468A1 (en) * | 2017-09-11 | 2019-03-14 | Christopher C. Miller | Enhanced immune response upon treatment with nitric oxide |
| US11472705B2 (en) * | 2018-03-13 | 2022-10-18 | Sanotize Research And Development Corp. | Nitric oxide releasing compositions |
| WO2020035739A1 (en) * | 2018-08-14 | 2020-02-20 | Regev Gilly | Devices and methods for quantifying nitric oxide |
| WO2020074957A1 (en) * | 2018-10-12 | 2020-04-16 | Sanotize Research And Development Corp. | Gas-evolving compositions and container and delivery systems |
-
2021
- 2021-07-16 JP JP2023502576A patent/JP2023533588A/ja active Pending
- 2021-07-16 AU AU2021307675A patent/AU2021307675A1/en active Pending
- 2021-07-16 MX MX2023000714A patent/MX2023000714A/es unknown
- 2021-07-16 US US18/016,655 patent/US20230285447A1/en active Pending
- 2021-07-16 EP EP21841913.3A patent/EP4125941A4/en active Pending
- 2021-07-16 CA CA3186075A patent/CA3186075A1/en active Pending
- 2021-07-16 BR BR112023000788A patent/BR112023000788A2/pt unknown
- 2021-07-16 CN CN202180063033.9A patent/CN116615188A/zh active Pending
- 2021-07-16 WO PCT/IB2021/000505 patent/WO2022013614A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022013614A1 (en) | 2022-01-20 |
| EP4125941A1 (en) | 2023-02-08 |
| CN116615188A (zh) | 2023-08-18 |
| BR112023000788A2 (pt) | 2023-05-09 |
| CA3186075A1 (en) | 2022-01-20 |
| WO2022013614A4 (en) | 2022-03-31 |
| EP4125941A4 (en) | 2024-04-10 |
| US20230285447A1 (en) | 2023-09-14 |
| JP2023533588A (ja) | 2023-08-03 |
| AU2021307675A1 (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Noronha-Dutra et al. | Reaction of nitric oxide with hydrogen peroxide to produce potentially cytotoxic singlet oxygen as a model for nitric oxide‐mediated killing | |
| MXPA06013111A (es) | Dosificacion intermitente de gas de oxido nitrico. | |
| MX2022008236A (es) | Metodos para administrar altas concentraciones de oxido nitrico. | |
| MX2023000714A (es) | Metodo de tratamiento de condiciones que responden a terapia con oxido nitrico. | |
| CY1109245T1 (el) | Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα | |
| MX2022013749A (es) | Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2). | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| PH12021551030A1 (en) | Antimicrobial gas releasing agents and systems and methods for using the same | |
| WO2012122028A3 (en) | Pyrazinoisoquinoline compounds | |
| EP0398207B1 (en) | Stable liquid form of 5-aminosalicylic acid | |
| Seddon et al. | Radiation chemistry of nitric oxide solutions | |
| MX2022010960A (es) | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. | |
| Gadomska et al. | Chain mechanism of the reactions of N, N′-diphenyl-1, 4-benzoquinone diimine with thiophenol and 1-decanethiol | |
| Riegelman et al. | Stabilization of epinephrine against sulfite attack | |
| Sherman | The γ-Radiolysis of Liquid 2-Propanol. Effect of Nitrous Oxide and Sulfuric Acid | |
| Cannon et al. | Long-lived binuclear intermediate in a cobalt (III)-iron (II) electron-transfer reaction | |
| MX2022014461A (es) | Nuevos abridores de canales de potasio maxi-k para el tratamiento de trastornos asociados con x fragil. | |
| McGill et al. | The kinetics of ammonia decomposition over vanadium nitride | |
| JP2013180931A (ja) | オゾンガスに含まれる窒素酸化物除去用吸着剤の前処理方法と窒素酸化物除去用吸着剤および前処理装置。 | |
| MX2022013465A (es) | Metodos para tratar eventos adversos relacionados con citocinas. | |
| US10526254B2 (en) | Iron-ion supply material | |
| Holroyd et al. | Pulse radiolysis of aqueous cyanogen solution | |
| MXPA03006359A (es) | Metodo para tratamiento del cancer. | |
| Barton et al. | Non-thermal atmospheric pressure plasma treatment of human cells: the effect of ambient conditions | |
| Houee-Levin et al. | Radiolysis Study of the Alloxan-Dialuric Acid Couple: I. The Reduction of Alloxan by e aq− and· COO− Radicals |